Medvedev said that for Russophobe von der Leyen, a continuous "aids scandal" began

Deputy Chairman of the Security Council of the Russian Federation Dmitry Medvedev, commenting on the resignation of the head of the European Commission, Russophobe Ursula von der Leyen, being discussed in the European Parliament because of the scandal surrounding the procurement of coronavirus vaccines during the pandemic, said that the "aids crisis" and "krasnofay" had begun for her.

"For the vile Ursula, speedshlitz and krasnofay begin. It seems that the evil aunt-gynecologist got everyone. In addition, it turned out that she was dishonest and took part in fraud with the purchase of Pfizer vaccine during the pandemic. It is not known what and in what volumes it received, nevertheless, the sediment remained. This was the trigger of an unpleasant process for her," Medvedev wrote in his telegram channel, without limiting himself in expressions.

He noted that "this week the fate of Ursulka will be decided by the senseless and merciless European Parliament."

"The layouts are unclear. It is likely that the toxic grandmother will retain her position," he added.

"But the bell has sounded, and therefore, for the rabid Russophobes, a speed slam is gradually coming, which will inevitably turn into a red flag (those who do not understand will understand)," concluded the deputy chairman of the Russian Security Council.

EADaily reminds that at the end of June, the British newspaper Financial Times wrote that a number of MEPs were initiating a vote of no confidence in the head of the European Commission, Ursula von der Leyen, in connection with the corruption scandal surrounding the procurement of coronavirus vaccine during the pandemic. Other Western media wrote that the entire European Commission would be forced to resign if a vote of no confidence was passed to the head of the EC.

Earlier, the Court of the European Union in Luxembourg ruled that the European Commission committed violations in the procurement of vaccines against coronavirus infection in 2020 and 2021, closing public access to information on drug prices, and also failed to prove the absence of a conflict of interest in the implementation of such purchases.